38173-66-9

Basic information

• Product Name: H-GLY-LEU-NH2 HCL
• Synonyms: H-GLY-LEU-NH2 HCL;GLY-L-LEU NH2 HCL;GLY-LEU AMIDE HYDROCHLORIDE
• CAS NO: 38173-66-9
• Molecular Formula: C₈H₁₇N₃O₂*ClH
• Molecular Weight: 223.7
• Product Categories: Dipeptides;Dipeptides and Tripeptides;Peptides
• Mol File: 38173-66-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: −20°C
• CAS DataBase Reference: H-GLY-LEU-NH2 HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-GLY-LEU-NH2 HCL(38173-66-9)
• EPA Substance Registry System: H-GLY-LEU-NH2 HCL(38173-66-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 38173-66-9(Hazardous Substances Data)

Usage

General Description

H-GLY-LEU-NH2 HCL is a synthetic peptide that consists of the amino acids glycine (Gly), leucine (Leu), and an amide group (NH2) with a hydrochloride salt (HCL) attached to the carboxy terminus. This peptide is often used in research and pharmaceutical applications as a model structure for studying peptide conformation and interactions, as well as in drug development and design. The hydrochloride salt form of the peptide provides increased stability and solubility in aqueous solutions, making it suitable for various laboratory and industrial uses. Additionally, the peptide may also have potential therapeutic applications in the treatment of certain diseases and disorders.

Upstream product

• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 89226-19-7 tert-butyloxycarbonylleucyl-glycine amide 

Downstream Products

• 103225-09-8 Boc-Pip-Leu-Gly-NH2 
• 2002-44-0 melanostatin 
• 16295-99-1 L-piperidine-2-carbonyl-L-leucylglycinamide hydrochloride 
• 14485-80-4 benzoyloxycarbonylprolyl-leucyl-glycine amide 
• 7672-21-1 (Z)-D-Pro-Leu-Gly-NH₂ 

Relevant articles and documents

Synthesis of an MIF-1 analogue containing enantiopure (S)-α- trifluoromethyl-proline and biological evaluation on nociception

The synthesis and the effect of a novel MIF-1 analogue on nociception during acute pain in rat model are reported. The synthesis of this enantiopure trifluoromethyl group containing tripeptide was performed through a peptide coupling reaction between the HCl. Leu-Gly-NH2 and the (S)-α-Tfm-proline. The analgesic effect of the CF3-(MIF-1) 2 has been evaluated in vivo on rat model by paw pressure (PP) and hot plate (HP) tests and compared to the native peptide MIF-1. Highest analgesic effect was observed with CF3-(MIF-1) 2 only in PP test. In order to study the mechanisms of nociception induced by the studied peptides, the involvement of the opioid and the nitric oxideergic systems was investigated. The results are in favor of a participation of both system since pretreatment, 20 min before injection of the CF3-(MIF-1) 2, with the non-competitive antagonist of opiate receptors naloxone, the nitric oxide synthase (NOS) inhibitor l-N G-nitroarginine ester (l-NAME) or the nitric oxide (NO) donor l-arginine (l-Arg) significantly decreased the pain perception in PP and HP tests.